北京北陆药业股份有限公司 股票代码：300016 股票简称：北陆药业 公告编号：2025-113 第九届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）第九届董事会第五次 会议于2025年10月27日下午以现场及通讯相结合的方式召开，会议通知以邮 件方式送达各位董事。本次会议应出席董事9人，实际出席董事9人，实际参 加表决董事9人。本次会议的召集召开程序符合《公司法》和《公司章程》的 有关规定。会议由董事长王旭先生主持，与会董事以记名投票方式审议通过 了以下议案： 一、《2025年第三季度报告》 董事会审议通过《2025 年第三季度报告》。 具体内容详见公司于巨潮资讯网（www.cninfo.com.cn）等中国证监会指定 信息披露网站披露的《2025 年第三季度报告》，《2025 年第三季度报告披露提 示性公告》同时刊登在公司指定信息披露报刊：《中国证券报》、《证券时报》 及《上海证券报》。 本报告已经公司第九届董事会审计委员会第四次会议审议通过。 本议案尚需提交2025年第四次临时股东 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥288,476,088.66, representing a year-on-year increase of 12.78%[4] - Net profit attributable to shareholders for Q3 2025 was ¥14,209,974.14, a significant increase of 192.80% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,938,214.59, down 35.49% year-on-year[4] - Total operating revenue for the current period reached ¥872,684,962.37, an increase of 19.5% compared to ¥729,717,058.01 in the previous period[27] - Net profit for the current period was ¥39,465,985.79, representing a 107.5% increase from ¥19,003,632.36 in the previous period[28] - Operating profit increased to ¥45,817,686.82, compared to ¥22,903,585.39 in the last period, reflecting a growth of 100.1%[27] - Basic earnings per share improved to ¥0.0870 from ¥0.0497, reflecting a 74.5% increase[28] Assets and Liabilities - Total assets at the end of Q3 2025 amounted to ¥3,221,782,955.47, reflecting an 8.20% increase from the end of the previous year[6] - The company's total assets rose to ¥3,221,782,955.47, up from ¥2,977,531,229.66, marking an 8.2% increase[25] - Total liabilities decreased to ¥852,799,245.56 from ¥1,148,042,995.20, a reduction of 25.7%[25] - Shareholders' equity attributable to the company reached ¥2,211,059,191.73, up 32.59% from the end of the previous year[6] - The equity attributable to shareholders of the parent company increased to ¥2,211,059,191.73, compared to ¥1,667,588,937.34, a growth of 32.6%[25] Cash Flow - Cash flow from operating activities for the year-to-date was ¥129,222,252.74, a decrease of 6.06% compared to the previous year[4] - The company reported a significant increase in cash flow from operating activities, contributing to improved liquidity and financial stability[29] - Cash inflow from operating activities totaled $926.44 million, an increase of 7.1% from $864.98 million in the previous period[30] - The net cash flow from operating activities was $129.22 million, a decrease of 6.5% from $137.57 million in the previous period[30] - Total cash and cash equivalents at the end of the period reached $305.93 million, up from $244.77 million in the previous period[32] Investments and Financing - The company reported a net cash outflow from investing activities of ¥140,143,400, a decrease of 77.60% year-on-year[11] - Net cash outflow from investment activities was $140.14 million, an improvement from a net outflow of $625.66 million in the previous period[32] - Cash paid for the purchase of fixed assets and intangible assets was $168.50 million, significantly higher than $74.53 million in the previous period[31] - Cash inflow from financing activities was $309.70 million, compared to $148.37 million in the previous period, marking a significant increase[32] Research and Development - R&D expenses for the period were ¥24,935,800, representing a 40.72% increase year-on-year, impacting net profit attributable to shareholders[10] - Research and development expenses for the current period were ¥63,963,081.76, up from ¥53,171,942.94, indicating a 20.3% increase[27] Market and Regulatory Developments - The company received market access qualifications for iodine contrast agents in South Korea and India in March and July 2025, respectively[19] - The company obtained GMP certification from Brazil's National Health Surveillance Agency in September 2025[19] Shareholder Information - The total number of restricted shares at the end of the period was 758,475, down from 772,075 at the beginning of the period[18] - The company plans to issue shares to specific targets through a simplified procedure in 2025[19]

Policy Developments - The National Health Commission emphasizes the construction of a fertility-friendly society, promoting supportive policies for childbirth, elderly care, and the gradual delay of retirement age to optimize population structure [1] Drug Approval - East China Pharmaceutical's subsidiary received approval for the drug Mevanertinib, a new treatment for advanced or metastatic non-small cell lung cancer, with a direct R&D investment of approximately 306 million yuan [2] - Hengrui Medicine's subsidiary received approval for a fixed-dose combination of three oral diabetes medications, marking the first of its kind in China [3] Financial Reports - Shuanglu Pharmaceutical reported a 143.28% year-on-year increase in net profit for Q3, driven by gains from financial assets [4] - Huitai Medical announced a 18.02% increase in net profit for the first three quarters, with Q3 revenue up 24.77% [5] Capital Market - WuXi AppTec plans to sell 100% equity of two subsidiaries for 2.8 billion yuan to focus on its CRDMO business model, enhancing its global capabilities [7] Industry Events - The Ministry of Industry and Information Technology conducted a survey on the traditional Chinese medicine industry, aiming to promote modernization and quality improvement [8] - Shanghai's biopharmaceutical industry is projected to exceed 1 trillion yuan, marking it as the fifth trillion-level industry in the city [9] - The Jiangxi Pharmaceutical Development Conference resulted in the signing of 16 key pharmaceutical projects across various sectors [10] Public Sentiment - Beilu Pharmaceutical announced that a major shareholder plans to reduce its stake by up to 1.78% to improve asset liquidity [11]

Core Insights - On October 24, seven A-share listed companies disclosed share reduction plans, with no companies announcing share increases on the same day [1]. Summary by Company - **Beilu Pharmaceutical**: Shareholder Sanxia Paint plans to reduce its stake by no more than 1.78% [2]. - **Abison**: Controlling shareholder Ding Yanhui intends to reduce his stake by no more than 3% [2]. - **Zhongke Feice**: Shareholder Guotou Chuangye Fund plans to reduce its stake by no more than 3% [2]. - **Liyang Chip**: Controlling shareholder and actual controller Huang Jiang plans to reduce his stake by no more than 600,000 shares [2]. - **Qifan Cable**: Controlling shareholder and actual controllers plan to collectively reduce their stake by no more than 3.5% [2]. - **Shangtai Technology**: Shareholder Changjiang Changdao plans to reduce his stake by no more than 2% [2]. - **Huayang Group**: Shareholders Zhongshan Zhongke and Zhongke Baiyun plan to collectively reduce their stake by no more than 1.5% [2].

Core Viewpoint - On October 24, seven A-share listed companies disclosed share reduction plans, with no companies announcing share increases on the same day [1]. Group 1: Company Share Reduction Details - Beilu Pharmaceutical: Shareholder Sanxia Paint plans to reduce its stake by no more than 1.78% [2]. - Aibisen: Controlling shareholder Ding Yanhui intends to reduce his stake by no more than 3% [2]. - Zhongke Feicai: Shareholder Guotou Chuangye Fund plans to reduce its stake by no more than 3% [2]. - Liyang Chip: Controlling shareholder and actual controller Huang Jiang plans to reduce his stake by no more than 600,000 shares [2]. - Qifan Cable: Controlling shareholder and actual controllers plan to collectively reduce their stake by no more than 3.5% [2]. - Shangtai Technology: Shareholder Changjiang Changdao plans to reduce its stake by no more than 2% [2]. - Huayang Group: Shareholders Zhongshan Zhongke and Zhongke Baiyun plan to collectively reduce their stake by no more than 1.5% [2]. Group 2: Market Signals - The formation of a MACD golden cross signal indicates a positive trend for these stocks [2].

Performance Disclosure - Chifeng Jilong Gold reported a 140.98% year-on-year increase in net profit attributable to shareholders in Q3, with revenue of 3.372 billion yuan, up 66.39% [1] - Guoxuan High-Tech achieved a staggering 1434.42% increase in net profit attributable to shareholders in Q3, with revenue of 10.114 billion yuan, up 20.68% [2] - Sichuan Changhong saw a 690.83% increase in net profit attributable to shareholders in Q3, despite a 2.69% decline in revenue to 25.184 billion yuan [3] - CITIC Securities reported a 51.54% increase in net profit attributable to shareholders in Q3, with revenue of 22.775 billion yuan, up 55.71% [4] Shareholding Changes - Beilu Pharmaceutical announced that its shareholder, Chongqing Three Gorges Paint Co., plans to reduce its stake by up to 1.78%, equivalent to no more than 10 million shares [5] - Zhejiang Liming disclosed that its shareholder, Yifan Investment, reduced its stake by 2.84%, totaling approximately 4.17 million shares [6] - Diou Waterhua revealed plans for shareholder Wang Zhihong to increase his stake by 100 million to 200 million yuan within six months [7] Risk Matters - Aowei New Materials indicated a potential application for stock suspension due to significant price deviations from its fundamental situation [8] - Wentai Technology warned of potential risks for revenue, profit, and cash flow adjustments if control issues are not resolved by the end of 2025 [9][10] - ST Chuangyi faced a fine of 4 million yuan for violations related to information disclosure, affecting several key executives with individual fines [11]

Group 1: Financial Performance - Dongfang Caifu reported a Q3 revenue of 4.733 billion yuan, a year-on-year increase of 100.65%, and a net profit of 3.53 billion yuan, up 77.74% year-on-year [1] - Guoxuan High-Tech announced a Q3 revenue of 10.114 billion yuan, a 20.68% increase year-on-year, and a net profit of 2.167 billion yuan, soaring 1434.42% year-on-year [2] - Jiangsu Power's controlling shareholder received a loan commitment of up to 7.2 billion yuan for stock repurchase [3] - Yueda Investment reported a Q3 revenue of 789 million yuan, a 22.97% increase year-on-year, and a net profit of 615.22 million yuan, up 333.60% year-on-year [4] Group 2: Strategic Investments - Yueda Investment formed joint ventures with China Resources Power and others to invest in offshore wind power projects, holding 20% and 30% stakes in two projects [4] - Hunan Development signed an investment agreement for a photovoltaic power generation project with a total investment of approximately 2.4 billion yuan [7] - Wiston plans to acquire a 36.7483% stake in Liangtou Technology and increase its capital, making it a subsidiary [10] Group 3: Market Trends and Risks - Shannon Chip announced significant stock price volatility, with a cumulative deviation of over 200% in 30 trading days, indicating potential irrational speculation [5] - Cambridge Technology set its H-share issuance price at 68.88 HKD per share, with trading expected to start on October 28, 2025 [6] Group 4: Company-Specific Developments - Jin Cai Hulin reported a Q3 net profit increase of 1697.84% despite a revenue decline [11] - Morning Light Bio's Q3 net profit grew by 385.3% despite a revenue drop [12] - Donggang Co. reported a Q3 net profit increase of 373.51% with a revenue increase of 45.80% [13] - Xinjiang Tianye's Q3 net profit increased by 363.19% despite a revenue increase of only 8.6% [14]

Group 1 - The core point of the news is that Chongqing Three Gorges Paint Co., Ltd., a shareholder of Beilu Pharmaceutical, plans to reduce its holdings by up to 10 million shares, which represents 1.78% of the company's total share capital [1] - Beilu Pharmaceutical's revenue composition for the year 2024 is primarily from drug production, accounting for 98.88%, while other business income constitutes 1.12% [1] - As of the latest report, Beilu Pharmaceutical has a market capitalization of 4.8 billion yuan [2]

格隆汇10月24日｜北陆药业公告，持股6.66%的股东重庆三峡油漆股份有限公司拟自公告披露日起15个 交易日后的3个月内，通过集中竞价、大宗交易或两者结合方式减持不超过1000万股，占公司总股本 1.78%；其中，通过集中竞价方式减持比例不超过1%，通过大宗交易方式减持比例不超过2%；减持原 因系提高资产流动性和使用效率。 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-108 北京北陆药业股份有限公司 持有北京北陆药业股份有限公司（以下简称"公司"）股份37,465,700股 （占公司总股本比例6.66%）的股东重庆三峡油漆股份有限公司（以下简称"三 峡油漆"）计划自本公告披露之日起15个交易日后的3个月内，以集中竞价、 大宗交易或两者相结合的方式减持不超过1,000万股公司股份（占公司总股本 比例1.78%）。 公司于近日收到公司持股5%以上股东三峡油漆出具的《股份减持计划告 知函》，现将相关事项公告如下： 一、股东的基本情况 1、股东名称：三峡油漆 2、股东持股情况：截至本公告日，三峡油漆持有公司股份 37,465,700 股， 占公司总股本比例 6.66%（公司回购专用账户中的股份数量为 0 股，所有股份 1 关于持股5%以上股东减持股份的预披露公告 公司持股5%以上的股东重庆三峡油漆股份有限公司保证向公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 计算均已剔除回购专用账户影响）。 二、本次减持计 ...